ONCS
Closed
Oncosec Medical Inc
0.0002
0.0000 (0.00%)
Last Update: 25 Aug 2023 16:30:00
Yesterday: 0.0002
Day's Range: 0.0002 - 0.0002
Send
sign up or login to leave a comment!
When Written:
1.12
OncoSec Medical Inc is a biotechnology company that develops cancer immunotherapies. The company's proprietary technology, ImmunoPulse, is designed to enhance the body's natural immune response to cancer. OncoSec's lead product candidate, ImmunoPulse IL-12, is currently in clinical trials for the treatment of metastatic melanoma and triple-negative breast cancer. The company is also developing other product candidates, including ImmunoPulse PD-1, which is designed to target the PD-1 checkpoint pathway, and ImmunoPulse CTLA-4, which is designed to target the CTLA-4 checkpoint pathway. OncoSec is headquartered in San Diego, California.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
1.12
OncoSec Medical Inc. is a biotechnology company that focuses on developing immunotherapy treatments for cancer. The company's proprietary technology, called ImmunoPulse, is designed to enhance the delivery and effectiveness of cancer-fighting agents, such as checkpoint inhibitors and vaccines.
OncoSec's lead product candidate is called TAVO (tavokinogene telseplasmid), which is a DNA-based immunotherapy that is designed to activate the immune system to attack cancer cells. TAVO is currently being evaluated in clinical trials for the treatment of various types of cancer, including melanoma, triple-negative breast cancer, and head and neck cancer.
In addition to TAVO, OncoSec is also developing other immunotherapy products, including ImmunoPulse IL-12, which is designed to stimulate the immune system to attack cancer cells by delivering the cytokine interleukin-12 directly to the tumor site.
OncoSec was founded in 2008 and is headquartered in San Diego, California. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol ONCS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
OncoSec's lead product candidate is called TAVO (tavokinogene telseplasmid), which is a DNA-based immunotherapy that is designed to activate the immune system to attack cancer cells. TAVO is currently being evaluated in clinical trials for the treatment of various types of cancer, including melanoma, triple-negative breast cancer, and head and neck cancer.
In addition to TAVO, OncoSec is also developing other immunotherapy products, including ImmunoPulse IL-12, which is designed to stimulate the immune system to attack cancer cells by delivering the cytokine interleukin-12 directly to the tumor site.
OncoSec was founded in 2008 and is headquartered in San Diego, California. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol ONCS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!